Preclinical News and Research

RSS

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Life Technologies Corporation (NASDAQ:LIFE) today announced results for its third quarter ended September 30, 2009. Non-GAAP revenue for the third quarter was $805 million, an increase of 3 percent over third quarter revenue of $784 million in 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 27 Oct 2009

Astellas enters into agreement with Medivation to develop MDV3100

Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer.

27 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

International experts discuss ion radiation therapy

The largest congress worldwide on the topic of particle or ion therapy - radiation with heavy ions and protons - has taken place in the fall of 2009 in Heidelberg. Well over 600 international participants, especially from Japan and the USA, convened in the Heidelberg Town Hall for the annual meeting of the "Particle Therapy Cooperative Group" (PTCOG), including leading experts from the fields of radiation therapy, medical physics and oncology.

27 Oct 2009

FDA orders spinal system manufacturers to conduct postmarket surveillance studies on their products

The U.S. Food and Drug Administration today ordered manufacturers of certain types of pedicle screw systems, called dynamic stabilization systems, to conduct postmarket surveillance studies to collect clinical data on a number of potential safety issues, including fusion rates and frequency of additional surgeries.

27 Oct 2009

Researchers identify how Tissue Factor contributes to cancer growth

A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists.

27 Oct 2009

Champions Biotechnology expands collaboration to accelerate oncology drug development

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

Major fundraising initiative launched for Rett syndrome research

Inspired by recent breakthroughs in research, today the International Rett Syndrome Foundation (IRSF) announced a major fundraising initiative entitled Research to Reality: Funding Progress. Funds raised by the campaign are earmarked to accelerate the progress of crucial research, and bring promise to reality. Country music sensation Clint Black, whose niece Courtney lost her battle with Rett syndrome in 2003 at age 16, will serve as Honorary Chair of the campaign.

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Scientists discover new way to help save lives threatened by traumatic injuries

A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.

26 Oct 2009

Human clinical trials of TissuGlu to commence in Germany

Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials of its lead product TissuGlu® in Germany. Receipt of the approval allows Cohera Medical to proceed with patient recruitment and initiation of an investigational study of the company's novel internal surgical adhesive being developed for its first intended use to adhere surgical tissues together in large flap surgeries.

24 Oct 2009

MPI Research to assist Kineta in autoimmune drug development program

MPI Research, a preclinical Contract Research Organization (CRO), announced that it will be collaborating with Kineta, Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system.

24 Oct 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Medgenics is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia.

23 Oct 2009

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Biotech company Pharming Group NV announced today publication of a preclinical study showing the benefit of using recombinant human C1 inhibitor (rhC1INH) in ischemic brain injury.

23 Oct 2009

Families of Spinal Muscular Atrophy and Repligen partner to develop a treatment for SMA

Families of Spinal Muscular Atrophy (FSMA) announced today that it has entered into a groundbreaking exclusive license agreement with Repligen Corporation for the development of a potential treatment of Spinal Muscular Atrophy (SMA).

23 Oct 2009

MedImmune announces interim data from its live attenuated influenza vaccine studies

MedImmune announced today that interim data from human studies of its nasal spray vaccine for the 2009 novel Influenza A (H1N1) virus demonstrate a similar clinical profile in children and adults 2 to 49 years of age as previously studied seasonal formulations of the vaccine.

23 Oct 2009

Preclinical News and Research

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Astellas enters into agreement with Medivation to develop MDV3100

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

International experts discuss ion radiation therapy

FDA orders spinal system manufacturers to conduct postmarket surveillance studies on their products

Researchers identify how Tissue Factor contributes to cancer growth

Champions Biotechnology expands collaboration to accelerate oncology drug development

Innovative approach to build a new drug to treat a number of CNS diseases

Major fundraising initiative launched for Rett syndrome research

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Scientists discover new way to help save lives threatened by traumatic injuries

Human clinical trials of TissuGlu to commence in Germany

MPI Research to assist Kineta in autoimmune drug development program

Seattle Genetics reports its third-quarter financial results

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Families of Spinal Muscular Atrophy and Repligen partner to develop a treatment for SMA

MedImmune announces interim data from its live attenuated influenza vaccine studies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News